Vaximm Strengthens Leadership with Appointment of Sébastien Wieckowski as Chief Scientific Officer Vaximm's recent appointment of Sébastien Wieckowski, PhD, as CSO exemplifies its commitment to advancing its pioneering oral immunotherapy platform aimed at cancer treatment.

Vaximm Strengthens Leadership with Appointment of Sébastien Wieckowski as Chief Scientific Officer #USA #Bellevue #VXM01 #Vaximm #Sébastien_Wieckowski

Vaximm AG Shortens Exclusivity Period with BCM Europe to Enhance Licensing Negotiations Vaximm AG announces an updated term sheet with BCM Europe, reducing the exclusivity period to three months to expedite licensing negotiations for its cancer immunotherapy.

Vaximm AG Shortens Exclusivity Period with BCM Europe to Enhance Licensing Negotiations #United_States #Bellevue #VXM01 #Vaximm_AG #BCM_Europe

Vaximm AG Partners with BCM Europe for VXM01 Licensing: A $20M Deal In a significant development, Vaximm AG has entered a $20M term sheet with BCM Europe to explore a potential licensing agreement for VXM01.

Vaximm AG Partners with BCM Europe for VXM01 Licensing: A $20M Deal #None #VXM01 #Vaximm_AG #BCM_Europe

Vaximm AG Unveils Promising Results from Their Phase 2a Trial of Innovative Glioblastoma Therapy Vaximm AG announced successful Phase 2a trial results, revealing the safety and potential efficacy of VXM01 combined with Avelumab for glioblastoma treatment.

Vaximm AG Unveils Promising Results from Their Phase 2a Trial of Innovative Glioblastoma Therapy #Switzerland #Basel #VXM01 #Avelumab #Vaximm_AG